August 20, 2025 a 08:38 am
DGX: Analysts Ratings - Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, a leader in diagnostic information services, shows a stable analyst sentiment with a predominant 'Hold' recommendation. Over recent months, a shift towards caution is noted, though strong buy signals remain minimal.
Historical Stock Grades
The latest analyst ratings for Quest Diagnostics Incorporated suggest a strong preference for holding the stock. Despite a challenging market environment, there has been little movement towards sell recommendations, underscoring confidence in the company’s fundamentals.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 8 | |
| Hold | 9 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
- The 'Hold' rating has become more prevalent, growing significantly in recent months.
- 'Strong Buy' ratings have remained consistently low, indicating cautious optimism.
- Overall, the decrease in 'Strong Buy' and 'Buy' recommendations points to a more conservative market approach.
Percentage Trends
Recent months have seen a subtle shift in sentiment towards holding rather than buying, with 'Hold' ratings constituting nearly half of all recommendations. This suggests increased caution among analysts:
- The share of 'Hold' recommendations has increased from 40% to 50% over the past year.
- 'Strong Buy' ratings have consistently remained below 10% throughout the period.
- This trend implies a steady outlook, with minimal pressure to either buy or sell the stock.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-07-23 | Hold | Hold | Deutsche Bank |
| 2025-07-23 | Hold | Hold | Truist Securities |
| 2025-07-23 | Neutral | Neutral | UBS |
| 2025-07-18 | Neutral | Neutral | UBS |
| 2025-05-06 | Neutral | Neutral | JP Morgan |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-03-04 | Neutral | Buy | Citigroup |
| 2025-01-06 | Outperform | Market Perform | Leerink Partners |
| 2024-12-17 | Overweight | Equal Weight | Morgan Stanley |
| 2024-10-23 | Outperform | Neutral | Baird |
| 2024-07-10 | Buy | Neutral | Citigroup |
Interpretation
The current sentiment surrounding Quest Diagnostics suggests a cautious but stable outlook. Analyst recommendations indicate minimal enthusiasm for aggressive buying, yet there is also no strong push towards selling, reflecting confidence in the company’s resilience.
While the predominance of 'Hold' ratings suggests some uncertainty, particularly given the competitive landscape, the stability in ratings changes implies a balanced view. Analysts appear to tread carefully given market conditions, with no immediate signs of either significant confidence or alarm among investors.
Conclusion
In summary, Quest Diagnostics Incorporated presents a profile of stability in an otherwise fluctuating market. The consistent 'Hold' ratings point to a cautious approach by analysts, underlined by a stable business model amidst an evolving industry. While opportunities exist for growth, particularly in diagnostic technology, risks include market volatility and competitive pressures. Analysts retain a balanced view, forecasting stability rather than significant upside or downside in the near term.